Incyte Corporation (($CC:INCY.CUR)) announced an update on their ongoing clinical study. Incyte Corporation recently completed a Phase 2 clinical ...

Discover a study exploring how GLP-1 receptor agonists may reduce symptoms of hidradenitis suppurativa through weight loss and anti-inflammatory effects.

Adults with hidradenitis suppurativa treated with adalimumab have a greater risk for serious infections than those with ...

(Nasdaq: ZURA) (“Zura Bio” or the “Company”), a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases with unmet needs, today ...

GLP-1 receptor agonists show promise in treating hidradenitis suppurativa, offering significant symptom relief and improved ...

Topline data from Phase 2 LOTUS trial of AVTX-009 for the treatment of hidradenitis suppurativa expected mid-2026Rita Jain, M.D. appointed to Board of DirectorsCash and short-term investments of ...

A multicenter French study led by Rennes University Hospital reports potential benefits of glucagon-like peptide-1 receptor ...

A significant burden of neuropsychiatric comorbidities exists among patients with PPD and various psychophysiological disorders.

Discover Insmed's innovative therapies targeting rare diseases, with approvals like Brinsupri boosting potential.

Discover a study validating a disease-specific quality-of-life tool for hidradenitis suppurativa, confirming its reliability, ...

We came across a bullish thesis on MoonLake Immunotherapeutics on Valueinvestorsclub.com by skimmer610. In this article, we will summarize the bulls’ thesis on MLTX. MoonLake Immunotherapeutics’s ...

Glucagon-like peptide-1 (GLP-1) receptor agonists show promise in reducing hidradenitis suppurativa severity and pain, especially in patients with obesity.